Trials / Completed
CompletedNCT01120418
Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days
A Randomized, Contralateral Study To Evaluate Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered 0.6% ISV-403 Three Times Daily For Five Days
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Bausch & Lomb Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to evaluate the effect on corneal endothelial cell density changes when ISV-403 is administered for five (5) days compared to no drug treatment, in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Besifloxacin Ophthalmic Suspension 0.6% | administered 3 times a day for 5 days to one eye. |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2007-10-01
- Completion
- 2008-02-01
- First posted
- 2010-05-11
- Last updated
- 2012-08-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01120418. Inclusion in this directory is not an endorsement.